LY2880070

Esperas Pharma Inc. · Phase 2 active Small molecule

At a glance

Generic name	LY2880070
Sponsor	Esperas Pharma Inc.
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Study of LY2880070 and Gemcitabine in People With Ewing Sarcoma,Ewing-Like Sarcoma, and Desmoplastic Small Round Cell Tumor (PHASE2)
A Study of LY2880070 in Participants With Advanced or Metastatic Cancer (PHASE1, PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

LY2880070 CI brief — competitive landscape report
LY2880070 updates RSS · CI watch RSS
Esperas Pharma Inc. portfolio CI